HK1254755A1 - 抗-肌肉生長抑制因子抗體、包含變體fc區的多肽及使用方法 - Google Patents

抗-肌肉生長抑制因子抗體、包含變體fc區的多肽及使用方法

Info

Publication number
HK1254755A1
HK1254755A1 HK18113798.7A HK18113798A HK1254755A1 HK 1254755 A1 HK1254755 A1 HK 1254755A1 HK 18113798 A HK18113798 A HK 18113798A HK 1254755 A1 HK1254755 A1 HK 1254755A1
Authority
HK
Hong Kong
Prior art keywords
regions
methods
polypeptides containing
myostatin antibodies
containing variant
Prior art date
Application number
HK18113798.7A
Other languages
English (en)
Chinese (zh)
Inventor
倉持太一
井川智之
堅田仁
堀裕次
Original Assignee
中外制藥株式會社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 中外制藥株式會社 filed Critical 中外制藥株式會社
Publication of HK1254755A1 publication Critical patent/HK1254755A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK18113798.7A 2015-12-18 2018-10-29 抗-肌肉生長抑制因子抗體、包含變體fc區的多肽及使用方法 HK1254755A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015247070 2015-12-18
PCT/JP2016/087487 WO2017104783A1 (en) 2015-12-18 2016-12-16 Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use

Publications (1)

Publication Number Publication Date
HK1254755A1 true HK1254755A1 (zh) 2019-07-26

Family

ID=59011957

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18113798.7A HK1254755A1 (zh) 2015-12-18 2018-10-29 抗-肌肉生長抑制因子抗體、包含變體fc區的多肽及使用方法

Country Status (16)

Country Link
EP (1) EP3390443A4 (ja)
JP (4) JP6142069B1 (ja)
KR (4) KR20240058997A (ja)
CN (2) CN115028721A (ja)
AR (1) AR107078A1 (ja)
AU (1) AU2016372934B2 (ja)
BR (1) BR112018011073A2 (ja)
CA (1) CA3002422C (ja)
EA (1) EA201891420A1 (ja)
HK (1) HK1254755A1 (ja)
MX (1) MX2018007145A (ja)
MY (1) MY189425A (ja)
PH (1) PH12018501280A1 (ja)
SG (2) SG10201707267RA (ja)
TW (3) TWI605057B (ja)
WO (1) WO2017104783A1 (ja)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5624276B2 (ja) 2006-03-31 2014-11-12 中外製薬株式会社 抗体の血中動態を制御する方法
EP3689912A1 (en) 2007-09-26 2020-08-05 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
TWI564021B (zh) 2008-04-11 2017-01-01 Chugai Pharmaceutical Co Ltd Repeated binding of antigen to antigen binding molecules
MX365235B (es) 2010-11-30 2019-05-28 Chugai Pharmaceutical Co Ltd Molécula de unión a antígeno capaz de unir repetidamente a la pluralidad de moléculas de antígeno.
CA2874721A1 (en) 2012-05-30 2013-12-05 Tomoyuki Igawa Target tissue-specific antigen-binding molecule
EP3597747B1 (en) 2012-08-24 2023-03-15 Chugai Seiyaku Kabushiki Kaisha Mouse fcgammarii-specific fc antibody
MX371442B (es) 2012-08-24 2020-01-30 Chugai Pharmaceutical Co Ltd VARIANTE DE LA REGION FC ESPECIFICA PARA FCyRIIB.
EP3783017A1 (en) 2013-04-02 2021-02-24 Chugai Seiyaku Kabushiki Kaisha Fc region variant
SG11201604495PA (en) 2013-12-04 2016-07-28 Chugai Pharmaceutical Co Ltd Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules
CA2963760A1 (en) 2014-12-19 2016-06-23 Yoshinao Ruike Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
EA201791754A1 (ru) 2015-02-05 2019-01-31 Чугаи Сейяку Кабусики Кайся АНТИТЕЛА, СОДЕРЖАЩИЕ ЗАВИСЯЩИЙ ОТ КОНЦЕНТРАЦИИ ИОНОВ АНТИГЕНСВЯЗЫВАЮЩИЙ ДОМЕН, ВАРИАНТЫ Fc-ОБЛАСТИ, IL-8-СВЯЗЫВАЮЩИЕ АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ
KR20240058997A (ko) * 2015-12-18 2024-05-03 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE
SG10201806693XA (en) * 2016-06-17 2018-09-27 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies and methods of use
CA3026050A1 (en) 2016-08-05 2018-02-08 Chugai Seiyaku Kabushiki Kaisha Composition for prophylaxis or treatment of il-8 related diseases
KR20190122739A (ko) 2017-02-28 2019-10-30 시애틀 지네틱스, 인크. 컨쥬게이션을 위한 시스테인 변이된 항체
SG11202003531WA (en) 2018-08-10 2020-05-28 Chugai Pharmaceutical Co Ltd Anti-cd137 antigen-binding molecule and utilization thereof
CN113906042A (zh) * 2019-04-10 2022-01-07 中外制药株式会社 用于纯化fc区修饰抗体的方法
AU2020346632A1 (en) * 2019-09-13 2022-05-05 Provincial Health Services Authority Anti-oncolytic virus antigen antibodies and methods of using same
RU2750267C1 (ru) * 2020-02-07 2021-06-25 Общество с ограниченной ответственностью «НАУЧНО-ПРОИЗВОДСТВЕННОЕ ОБЪЕДИНЕНИЕ ИН-ВЕТ» Рекомбинантный ростовой дифференцировочный фактор роста 11 (GDF11), способ его получения, инъекционный препарат для повышения мышечной массы млекопитающих животных и птицы, а также способ использования препарата
TW202144395A (zh) 2020-02-12 2021-12-01 日商中外製藥股份有限公司 用於癌症之治療的抗cd137抗原結合分子
CN118055767A (zh) 2021-10-06 2024-05-17 豪夫迈·罗氏有限公司 新颖的组合施用
WO2023187022A1 (en) 2022-04-01 2023-10-05 F. Hoffmann-La Roche Ag New treatment for facioscapulohumeral muscular dystrophy (fshd)
US11780910B1 (en) 2022-05-02 2023-10-10 Novo Nordisk A/S Anti-ANGPTL3 antibodies suitable for high concentration compositions and subcutaneous administration
WO2024081932A1 (en) 2022-10-14 2024-04-18 Genentech, Inc. Methods for treating spinal muscular atrophy
CN116990528B (zh) * 2023-09-27 2024-02-06 成都华西海圻医药科技有限公司 一种基于Gyrolab平台快速测定抗CD40单抗的分析方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
AR047392A1 (es) * 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
CA2580796C (en) * 2004-09-24 2013-03-26 Amgen Inc. Modified fc molecules having peptides inserted in internal loop regions
US8008453B2 (en) * 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
AU2007292555B2 (en) * 2006-09-05 2012-05-31 Eli Lilly And Company Anti-myostatin antibodies
PE20091163A1 (es) * 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
TWI564021B (zh) 2008-04-11 2017-01-01 Chugai Pharmaceutical Co Ltd Repeated binding of antigen to antigen binding molecules
UY32341A (es) 2008-12-19 2010-07-30 Glaxo Group Ltd Proteínas de unión antígeno novedosas
EP2545079A2 (en) * 2010-03-11 2013-01-16 Rinat Neuroscience Corporation ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
AR081556A1 (es) * 2010-06-03 2012-10-03 Glaxo Group Ltd Proteinas de union al antigeno humanizadas
LT2883449T (lt) * 2012-03-16 2018-05-10 Regeneron Pharmaceuticals, Inc. Histidinu modifikuoti lengvosios grandinės antikūnai ir juos gaminantys genetiškai modifikuoti graužikai
TWI619729B (zh) * 2012-04-02 2018-04-01 再生元醫藥公司 抗－ｈｌａ－ｂ*２７抗體及其用途
CN104540852B (zh) * 2012-08-13 2018-10-02 瑞泽恩制药公司 具有pH-依赖性结合特性的抗-PCSK9抗体
MX371442B (es) * 2012-08-24 2020-01-30 Chugai Pharmaceutical Co Ltd VARIANTE DE LA REGION FC ESPECIFICA PARA FCyRIIB.
LT2981822T (lt) * 2013-05-06 2020-12-28 Scholar Rock, Inc. Kompozicijos ir būdai, skirti augimo faktoriaus moduliacijai
TN2016000057A1 (en) * 2013-08-14 2017-07-05 Novartis Ag Methods of treating sporadic inclusion body myositis
WO2016073879A2 (en) * 2014-11-06 2016-05-12 Scholar Rock, Inc. Transforming growth factor-related antibodies and uses thereof
CA3005158A1 (en) * 2014-11-06 2016-05-12 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
CA2963760A1 (en) * 2014-12-19 2016-06-23 Yoshinao Ruike Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
KR20240058997A (ko) 2015-12-18 2024-05-03 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법

Also Published As

Publication number Publication date
RU2018125431A3 (ja) 2020-07-06
JP7053164B2 (ja) 2022-04-12
TW202231662A (zh) 2022-08-16
EA201891420A1 (ru) 2019-02-28
MX2018007145A (es) 2018-08-15
AU2016372934A1 (en) 2018-05-10
KR101820637B1 (ko) 2018-01-19
CA3002422A1 (en) 2017-06-22
CN108473562B (zh) 2022-06-17
CN108473562A (zh) 2018-08-31
KR20240058997A (ko) 2024-05-03
SG10201707267RA (en) 2017-10-30
KR20230027321A (ko) 2023-02-27
TW201726718A (zh) 2017-08-01
PH12018501280A1 (en) 2019-01-28
JP2017148069A (ja) 2017-08-31
WO2017104783A1 (en) 2017-06-22
KR20180085711A (ko) 2018-07-27
EP3390443A1 (en) 2018-10-24
TWI749057B (zh) 2021-12-11
JP2017112997A (ja) 2017-06-29
MY189425A (en) 2022-02-10
JP2024023427A (ja) 2024-02-21
SG11201610812WA (en) 2017-07-28
KR20170085028A (ko) 2017-07-21
CN115028721A (zh) 2022-09-09
TW201808992A (zh) 2018-03-16
KR102501335B1 (ko) 2023-02-17
JP6142069B1 (ja) 2017-06-07
JP2022097485A (ja) 2022-06-30
AU2016372934B2 (en) 2023-10-05
BR112018011073A2 (pt) 2018-11-21
EP3390443A4 (en) 2019-11-13
RU2018125431A (ru) 2020-01-20
TWI605057B (zh) 2017-11-11
AR107078A1 (es) 2018-03-21
CA3002422C (en) 2024-04-16

Similar Documents

Publication Publication Date Title
IL278014A (en) Anti-myostatin antibodies, polypeptides containing variable FC regions and methods of use
HK1254755A1 (zh) 抗-肌肉生長抑制因子抗體、包含變體fc區的多肽及使用方法
IL264590A (en) fc region-containing polypeptides and uses thereof
HK1246312A1 (zh) 抗ceacam6抗體及其用途
IL258397A (en) Anti-aging antibodies and methods of using them
HK1246321A1 (zh) 包含glp和免疫球蛋白雜合fc的融合多肽及其用途
SG11201705585QA (en) Anti-myostatin antibodies and methods of use
IL247096A0 (en) proteins fc multimers
SG11201709573YA (en) Specific modification of antibody with igg-binding peptide
IL265290A (en) Antibodies against dengue virus, proteins containing fc regions and methods of their use
PT3137505T (pt) Combinação de lenalidomida e construção polipeptídica e utilizações desta
IL284291A (en) Anti-acth antibodies from humans and their use
HK1258166A1 (zh) 重組igg fc多聚體
EP3394098A4 (en) ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE
DK3197472T3 (da) Rekombinante phe-frie proteiner til anvendelse i behandlingen af phenylketonuri
SG11201606596PA (en) Multimeric fc proteins
ZA201804328B (en) Tetravalent anti-psgl-1 antibodies and uses thereof
PL3110447T3 (pl) Przeciwciało anty-EGFR i jego zastosowania
PT3096784T (pt) Péptidos, dispositivos e métodos para a deteção de anticorpos de anaplasma
HK1244534A1 (zh) 重組疏螺旋體蛋白及其使用方法
SG11201702539UA (en) Antibody-binding polypeptide, antibody-binding fusion polypeptide, and adsorption material
HK1252350A1 (zh) Mrka多肽、抗體及其用途
TH1701003441A (th) แอนติ-ไมโอสแตตินแอนติบอดี, โพลีเปปไทด์ที่ประกอบด้วยบริเวณแวเรียน Fc และวิธีการของการใช้
GB201504211D0 (en) Use of peptides
GB201401973D0 (en) Antibody polypeptides and uses thereof